1. 1. Pagani, L., Migliavacca, R., Pallecchi, L., et al. (2002): Emerging extended-spectrum β-lactamases in Proteus mirabilis. J. Clin. Microbiol., 40, 1549–1552.
2. 2. Tenover, F.C., Emery, S.L., Spiegel, C.A., et al. (2009): Identification of plasmid-mediated Amp-C β-lactamases in Escherichia coli, Klebsiella spp., and Proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J. Clin. Microbiol., 47, 294–299.
3. 3. Tibbetts, R., Frye, J.G., Marschall, J., et al. (2008): Detection of KPC-2 in a clinical isolate of Proteus mirabilis and first reported description of carbapenemase resistance caused by a KPC β-lactamases in Proteus mirabilis. J. Clin. Microbiol., 46, 3080–3083.
4. 4. Clinical and Laboratory Standards Institute (CLSI) (2011): Performance standards for antimicrobial susceptibility testing: 21st informational supplement M100-S21. CLSI, Wayne, Pa, USA.
5. 5. Kenneth, S.T. (2010): Extended-spectrum β-lactamases, AmpC, and carbapenemase issues. J. Clin. Microbiol., 48, 1019–1025.